Glipizide and Lagophthalmos - a phase IV clinical study of FDA data

Summary:

Lagophthalmos is reported as a side effect among people who take Glipizide (glipizide), especially for people who are female, 30-39 old, also take Crestor, and have Osteoporosis.

The phase IV clinical study analyzes which people have Lagophthalmos when taking Glipizide. It is created by eHealthMe based on reports of 63,661 people who have side effects when taking Glipizide from the FDA, and is updated regularly.

What is Glipizide?

Glipizide has active ingredients of glipizide. It is often used in diabetes. eHealthMe is studying from 64,852 Glipizide users. Check the latest studies of Glipizide.

What is Lagophthalmos?

Lagophthalmos (the inability to close the eyelids completely) is found to be associated with 55 drugs and 112 conditions by eHealthMe. Check the latest studies of Lagophthalmos.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 14, 2026

63,661 people reported to have side effects when taking Glipizide.
Among them, 11 people (0.02%) have Lagophthalmos.

Among these 11 people:

What is the gender of people who have Lagophthalmos when taking Glipizide? *

female: 100 %
male: 0.0 %

What is the age of people who have Lagophthalmos when taking Glipizide? *

What are other drugs people take besides Glipizide? *

What are other side effects people have besides Lagophthalmos? *

Injury: 11 people, 100.00%
Fracture Nonunion (permanent failure of healing following a broken bone): 11 people, 100.00%
Osteitis (a general term for inflammation of bone): 11 people, 100.00%
Nearsightedness (difficulty in seeing the far objects): 11 people, 100.00%
Muscle Spasms (muscle contraction): 11 people, 100.00%
Muscle Aches (muscle pain): 11 people, 100.00%
Malaise (a feeling of general discomfort or uneasiness): 11 people, 100.00%
Lacrimation Increased: 11 people, 100.00%
Jaw Fracture: 11 people, 100.00%
Iron Deficiency Anaemia: 11 people, 100.00%

What are the existing conditions these people have? *

Osteoporosis (bones weak and more likely to break): 2 people, 18.18%

* Approximation only. Some reports may have incomplete information.

Do you take Glipizide and have Lagophthalmos?

- Check whether Lagophthalmos is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Glipizide:

Glipizide (64,852 reports)

Lagophthalmos treatments and more:

Lagophthalmos (474 reports)

Browse all side effects of Glipizide:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Lagophthalmos:

Lagophthalmos (55 drugs)

Browse all the conditions that are associated with Lagophthalmos:

Lagophthalmos (112 conditions)

Related publications that referenced our studies

Das S, Anand Ramasamy SD, Mondal S, "An unusual case of glipizide-induced proximal myopathy", Journal of pharmacology & pharmacotherapeutics, 2016 Jan .
Das S, Anand Ramasamy SD, Mondal S, "An unusual case of glipizide-induced proximal myopathy", Journal of pharmacology & pharmacotherapeutics, 2016 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on glipizide (the active ingredients of Glipizide) and Glipizide (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.